| |
 |
|
|
|
| |
|
 |
The
Atlantic
Team
Atlantic
Healthcare's
management team and Board have extensive experience in the sector,
with commercial and clinical backgrounds in major global groups
such as Eli Lily, Glaxo and Pfizer, as well as in building
smaller public and private companies including Chiroscience Group plc (acquired by Celltech Group plc), Alizyme
plc, Elan Pharmaceuticals and Lipoxen plc (AIM:
LPX.L)
The team is also experienced in mergers and acquisitions and the
funding of companies in the healthcare sector, in private equity
and public company environments and in successful company exits |
| |
|
| |
|
| |
Atlantic
Healthcare Management Team |
| |
|
|
Toby
Wilson Waterworth
(BSc Econ, ACA)
Chief Executive Officer
Atlantic
Healthcare Group
Senior
management expertise in successfully building and
growing healthcare companies including Robannic NV,
Chiroscience Group plc, Alizyme plc and Lipoxen plc
|
 |
Richard
Wood
Non-Executive Chairman - UK
Senior
management expertise in international public and private companies
including ICI, Daniels Pharmaceuticals and Lloyds
Chemists. Most recently CEO of FTSE 250 company
Genus plc. |
 |
Allan
Cambridge
(BSc, BPharm, MRPharmS)
Chief Operating Officer
Senior
management expertise including £28m MBO of Evans Medical
Ltd sold for £89m. Senior positions in GSK, Deloitte and
Touche, Wyeth, Alizyme plc, Lipoxen plc
|
 |
Huw
Jones
(BSc, PhD)
Chief Commercial Officer
Senior
management expertise in global pharma including CV
Therapeutics, recently acquired by Gilead Sciences Inc,
for $1.4 billion, Ashbourne Pharma centicals, Elan
Pharmaceuticals and GSK (SmithKline Beecham)
|
|
 |
Stephen
Jones (BSc, MBBS, MRCSEd, MFPM, Dip Pharm Med)
Chief Medical Officer
Medical
Doctor, ran successful Tysabri clinical trials and
registration in Crohn’s disease
Past
affiliations: Elan Pharmaceuticals, S.L.A. Pharma |
 |
Steve
Hobbs
(BSc)
Non-Executive Director - Australia
Senior
management expertise in global pharma including
Quintiles Transnational Inc., Innovex, Servier and
Boehringer Ingelheim, and a Director at Achieve Capital,
an Australian based corporate advisory firm specialising
in the pharmaceutical industry.
|
 |
Roger
Davies
(MA Econ)
Non-Executive Director - UK
Roger is a
senior international pharmaceutical executive with
experience most recently as Group Director, Licensing
and Business Development at Bioglan plc and previously
as Director of International Development at Mundipharma
Int'l
|
 |
James
Culverwell
(BSc)
Non-Executive Director - UK
James is
Partner at Sudbrook Associates LLP, a healthcare
boutique. Previously, James was Director of European
Healthcare Research at ABN AMRO and First Vice-President
Merrill Lynch Equity Research & Head of European
Healthcare Research |
 |
Thomas
Wellner
Non-Executive Director - USA
Thomas is
a highly experienced, international executive and sales
and marketing professional who was CEO for Lilly in Germany
then followed as President and CEO of Therapure
BioPharma
|
|
|
|
|
|
|
|
|
| |
|
| |
|
|
|
